Natick-based Aleta Biotherapeutics, a cancer treatment development company, has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to investigate a new therapeutic for lymphoma in a clinical trial.
Aleta will continue to receive funding anc clinical support from a previously established relationship with Cancer Research UK.
The trial will evaluate the functionality of Aleta’s lead treatment program, ALETA-001, in cancer patients with B-cell malignancies, which is a form of lymphoma, according to a Tuesday press release from Aleta.
“The authorization to clinically evaluate, in collaboration with Cancer Research UK, the potent activity of ALETA-001, our lead biologic CAR T-Cell Therapy Engager, marks important progress for the entire global oncology community – especially patients,” Paul Rennert, CEO and chief scientific officer at Aleta Biotherapeutics, said in the release.
Aleta is a privately-held corporation. Its clinical focus is on development of CAR-T cell cancer therapies and enhancements to allow patients to better tolerate the therapies.
